Geneos Therapeutics closes its Series A3 financing with investment of $5M

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced that it has completed its Series A3 financing round with an additional investment of $5 million, totaling $10 million. This investment adds Shanghai Healthcare Capital (SHC) to Geneos’ investor syndicate. Dr Jing Bao will join as a board observer, bringing extensive expertise in the pharmaceutical industry and with global clinical trials.

“We are pleased to add SHC to our investor syndicate and Dr Bao to our team. The depth of knowledge the SHC team brings as well as their network in China will be invaluable to Geneos, especially as we pursue hepatocellular (liver) cancer as our initial target,” stated Niranjan Sardesai, PhD., president and chief executive officer of Geneos Therapeutics.

“The results that Geneos has achieved to date in the clinic with its personalized therapeutic cancer vaccine are impressive, and we are pleased to support Geneos’ further clinical development of this important treatment,” stated Jing Bao, MD, partner of SHC.

Proceeds will fund completion of phase 1b/2a GT-30 program
GT-30 is evaluating the safety, and efficacy of PTCV (GNOS-PV02 plus plasmid-encoded IL-12) administered in combination with the immune checkpoint inhibitor pembrolizumab, in 36 patients with unresectable or metastatic hepatocellular carcinoma (HCC) who progress on, or are intolerant to, first-line tyrosine kinase inhibitors (sorafenib or lenvatinib). Study enrollment completed in June of this year with the top-line safety and clinical response data from the complete cohort of 36 patients is anticipated by the end of the year.
MB Bureau